KIT and gastrointestinal stromal tumor: This finding is consistent with the result of non-progressing GIST, where even targeting known oncogenic mutations of KIT failed to eradicate all the residual disease and drug interruption led to early tumor progression in advanced and adjuvant setting [29,30].